23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Ionis Pharmaceuticals, Inc. › 2025-2026

Ionis Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Ionis Pharmaceuticals, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 484Asset managers, any item
  • 3,318Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 6 items on Ionis Pharmaceuticals, Inc.’s Form 8-K, filed June 8, 2026: 4 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (14.8% against); 1 other board item (23.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Ionis Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ionis Pharmaceuticals, Inc.

These tallies are Ionis Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Ionis Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Spencer R. Berthelsen 119,824,35320,816,54798,115 --12,305,695 85%Passed (calculated)—
Elect Director: Joan E. Herman 135,599,6465,076,89562,474 --12,305,695 96%Passed (calculated)—
2. Advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed 135,537,9735,088,105112,937 --12,305,695 96%Approved—
3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc 108,377,08432,303,28858,643 --12,305,695 77%Approved—
4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan 140,348,001332,20458,810 --12,305,695 99.8%Approved—
5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year 148,893,6464,000,539150,525 --0 97%Approved—

Source: Ionis Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.

How asset managers voted at the Ionis Pharmaceuticals, Inc. 2025-2026 meeting

484 asset managers disclosed a vote on at least one Ionis Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Joan E. Herman

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 135,599,646AGAINST: 5,076,895
Details: description as filed, official tally, votes by 117 asset managers

Description as filed by funds: Election of Directors: Joan E. Herman

Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joan E. Herman”): 135,599,646 for, 5,076,895 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 117 asset managers below reported 81,013,475 for, 2,283,538 against, 1,764 abstained, 160 not voted.

FOR
FOR: 81,013,475AGAINST: 2,283,538ABSTAIN: 1,764NOT VOTED: 160
Largest asset managers voting on “Election of Directors: Joan E. Herman” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,414,46314 00For
Fidelity17,072,1700 00For
Capital Group15,689,0020 00For
T. Rowe Price3,173,5862,132,721 00Mixed
NEW ECONOMY FUND4,723,8020 00For
BlackRock3,679,1550 00For
TWEEDY, BROWNE FUND INC.1,963,1620 00For
Charles Schwab1,536,0940 00For
State Street1,308,4130 00For
JPMorgan1,296,9170 00For
American Century1,275,8490 00For
Jackson National982,7600 00For
Franklin Custodian Funds800,0000 00For
Waddell & Reed598,6360 00For
MUTUAL FUND SERIES TRUST594,5870 00For
MFS573,8890 00For
Invesco546,5180 00For
TIAA459,0610 00For
First Trust411,2050 00For
Neuberger Berman350,7450 00For
FRANKLIN STRATEGIC SERIES347,2720 00For
Goldman Sachs341,7910 00For
Bridge Builder Trust333,6370 00For
ARK ETF Trust269,7860 00For
MassMutual258,4300 00For

Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).

Elect Director: Spencer R. Berthelsen

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%AGAINST
FOR: 119,824,353AGAINST: 20,816,547
Details: description as filed, official tally, votes by 117 asset managers

Description as filed by funds: Election of Directors: Spencer R. Berthelsen

Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Spencer R. Berthelsen”): 119,824,353 for, 20,816,547 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 117 asset managers below reported 74,662,984 for, 8,634,029 against, 1,764 abstained, 160 not voted.

FOR
FOR: 74,662,984AGAINST: 8,634,029ABSTAIN: 1,764NOT VOTED: 160
Largest asset managers voting on “Election of Directors: Spencer R. Berthelsen” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,403,96710,510 00For
Fidelity17,072,1700 00For
Capital Group15,689,0020 00For
T. Rowe Price05,306,307 00Against
NEW ECONOMY FUND4,723,8020 00For
BlackRock3,679,1550 00For
TWEEDY, BROWNE FUND INC.1,963,1620 00For
Charles Schwab1,536,0940 00For
State Street4,0381,304,375 00Against
JPMorgan1,296,9170 00For
American Century1,275,8490 00For
Jackson National490,004492,756 00Mixed
Franklin Custodian Funds800,0000 00For
Waddell & Reed0598,636 00Against
MUTUAL FUND SERIES TRUST594,5870 00For
MFS573,8890 00For
Invesco546,5180 00For
TIAA459,0610 00For
First Trust411,2050 00For
Neuberger Berman350,7450 00For
FRANKLIN STRATEGIC SERIES347,2720 00For
Goldman Sachs341,7910 00For
Bridge Builder Trust333,6370 00For
ARK ETF Trust269,7860 00For
MassMutual8,419250,011 00Against

Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).

Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of…

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 140,348,001AGAINST: 332,204
Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the terminati”): 140,348,001 for, 332,204 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Ionis Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 123 asset managers below reported 83,839,011 for, 1,765 against, 160 not voted.

FOR
FOR: 83,839,011AGAINST: 1,765NOT VOTED: 160
Largest asset managers voting on “To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number o” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,414,4761 00For
Fidelity17,072,1700 00For
Capital Group15,689,0020 00For
T. Rowe Price5,306,3070 00For
NEW ECONOMY FUND4,723,8020 00For
BlackRock3,679,1550 00For
TWEEDY, BROWNE FUND INC.1,963,1620 00For
Charles Schwab1,536,0940 00For
State Street1,308,4130 00For
JPMorgan1,296,9170 00For
American Century1,275,8490 00For
Jackson National982,7600 00For
Franklin Custodian Funds800,0000 00For
Waddell & Reed598,6360 00For
MUTUAL FUND SERIES TRUST594,5870 00For
MFS573,8890 00For
Invesco546,5180 00For
Eversept Partners, LP498,8000 00For
TIAA459,0610 00For
First Trust411,2050 00For
Neuberger Berman350,7450 00For
FRANKLIN STRATEGIC SERIES347,2720 00For
Goldman Sachs341,7910 00For
Bridge Builder Trust333,6370 00For
ARK ETF Trust269,7860 00For

Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).

Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

77% Approved · of votes cast

FOR 77%AGAINST
FOR: 108,377,084AGAINST: 32,303,288
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc”): 108,377,084 for, 32,303,288 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 118 asset managers below reported 69,360,158 for, 13,792,761 against, 3,564 abstained, 160 not voted.

FORAGAINST
FOR: 69,360,158AGAINST: 13,792,761ABSTAIN: 3,564NOT VOTED: 160
Largest asset managers voting on “To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to ” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,414,372105 00For
Fidelity3,494,13913,578,031 00Mixed
Capital Group15,689,0020 00For
T. Rowe Price5,306,3070 00For
NEW ECONOMY FUND4,723,8020 00For
BlackRock3,679,1550 00For
TWEEDY, BROWNE FUND INC.1,963,1620 00For
Charles Schwab1,536,0940 00For
State Street1,308,40013 00For
JPMorgan1,296,9170 00For
American Century1,275,8490 00For
Jackson National982,7600 00For
Franklin Custodian Funds800,0000 00For
Waddell & Reed598,6360 00For
MUTUAL FUND SERIES TRUST594,5870 00For
MFS573,8890 00For
Invesco546,5180 00For
TIAA459,0610 00For
First Trust411,2050 00For
Neuberger Berman350,7450 00For
FRANKLIN STRATEGIC SERIES347,2720 00For
Goldman Sachs341,7910 00For
Bridge Builder Trust333,6370 00For
ARK ETF Trust269,7860 00For
MassMutual258,4300 00For

Showing the 25 largest of 118 asset managers. All 118 are in the interactive database (link above).

Advisory vote on the compensation paid to the Company's executive officers, including the following resolution…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 135,537,973AGAINST: 5,088,105

Prior year: 95.8% for (June 5, 2025 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 484 asset managers

Description as filed by funds: To make an advisory vote on executive compensation.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 135,537,973 for, 5,088,105 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 115 asset managers voting on “To make an advisory vote on executive compensation.” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,414,46611 00For
Fidelity17,072,1700 00For
Capital Group15,689,0020 00For
T. Rowe Price5,306,3070 00For
NEW ECONOMY FUND4,723,8020 00For
BlackRock3,679,1550 00For
TWEEDY, BROWNE FUND INC.1,963,1620 00For
Charles Schwab1,536,0940 00For
State Street1,308,4130 00For
JPMorgan1,296,9170 00For
American Century1,275,8490 00For
Jackson National831,772150,988 00Mixed
Franklin Custodian Funds800,0000 00For
Waddell & Reed598,6360 00For
MUTUAL FUND SERIES TRUST594,5870 00For
MFS573,8890 00For
Invesco0546,518 00Against
TIAA459,0610 00For
First Trust411,2050 00For
Neuberger Berman350,7450 00For
FRANKLIN STRATEGIC SERIES347,2720 00For
Goldman Sachs341,7910 00For
Bridge Builder Trust333,6370 00For
ARK ETF Trust269,7860 00For
MassMutual258,4300 00For

Fund voting reports, all 115 managers: 82,444,220 for, 780,603 against, 1,764 abstained, 160 not voted, 216 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 398 asset managers voting on “To make an advisory vote on executive compensation.” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity24,401,303165 00For
Capital Group21,161,9840 00For
T. Rowe Price9,154,7860 00For
Wellington5,622,9810 00For
BlackRock4,399,0500 00For
GEODE CAPITAL MANAGEMENT, LLC3,980,7540 00For
State Street3,181,0293,841 00For
RBC Global Asset Management (U.S.) Inc.2,322,1810 00For
Tweedy, Browne Co LLC2,158,9240 00For
DEERFIELD MANAGEMENT COMPANY, L.P.1,979,6690 00For
Deep Track Capital, LP1,748,4580 00For
Artisan1,693,5390 00For
Charles Schwab1,585,4780 00For
FRANKLIN ADVISERS INC1,567,6720 00For
Polar Capital Holdings Plc1,565,9320 00For
American Century1,363,0460 00For
PICTET ASSET MANAGEMENT SA1,318,5670 00For
Vanguard1,280,2270 00For
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC1,096,3740 00For
BNP Paribas Asset Management Holding S.A.0867,805 00Against
Invesco0858,410 00Against
UBS0846,683 00Against
Northern Trust793,1260 00For
GROUPAMA ASSET MANAGMENT743,3550 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST730,0200 00For

Institutional-manager reports, all 398 managers: 107,403,087 for, 4,098,388 against, 7,444 abstained, 2,683 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 148,893,646AGAINST: 4,000,539

Prior year: 97.0% for (June 5, 2025 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 117 asset managers

Description as filed by funds: To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year.

Ionis Pharmaceuticals, Inc.’s own tally for this item (“5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year”): 148,893,646 for, 4,000,539 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 117 asset managers below reported 83,278,949 for, 18,064 against, 1,764 abstained, 160 not voted.

FOR
FOR: 83,278,949AGAINST: 18,064ABSTAIN: 1,764NOT VOTED: 160
Largest asset managers voting on “To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal yea” at Ionis Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,404,02610,451 00For
Fidelity17,072,1700 00For
Capital Group15,689,0020 00For
T. Rowe Price5,306,3070 00For
NEW ECONOMY FUND4,723,8020 00For
BlackRock3,679,1550 00For
TWEEDY, BROWNE FUND INC.1,963,1620 00For
Charles Schwab1,536,0940 00For
State Street1,308,36449 00For
JPMorgan1,296,9170 00For
American Century1,275,8490 00For
Jackson National982,7600 00For
Franklin Custodian Funds800,0000 00For
Waddell & Reed598,6360 00For
MUTUAL FUND SERIES TRUST594,5870 00For
MFS573,8890 00For
Invesco546,5180 00For
TIAA459,0610 00For
First Trust411,2050 00For
Neuberger Berman350,7450 00For
FRANKLIN STRATEGIC SERIES347,2720 00For
Goldman Sachs341,7910 00For
Bridge Builder Trust333,6370 00For
ARK ETF Trust269,7860 00For
MassMutual258,4300 00For

Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).

Largest Ionis Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 165,262,556 shares outstanding at the time of that meeting.

Fund voting reports: top Ionis Pharmaceuticals, Inc. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 11.75%
2Fidelity 10.33%
3Capital Group 9.49%
4T. Rowe Price 3.21%
5NEW ECONOMY FUND 2.86%
6BlackRock 2.23%
7TWEEDY, BROWNE FUND INC. 1.19%
8Charles Schwab 0.93%
9State Street 0.79%
10JPMorgan 0.78%
Institutional-manager reports: top Ionis Pharmaceuticals, Inc. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.77%
2Capital Group 12.81%
3T. Rowe Price 5.54%
4Wellington 3.40%
5BlackRock 2.66%
6GEODE CAPITAL MANAGEMENT, LLC 2.41%
7State Street 1.93%
8RBC Global Asset Management (U.S.) Inc. 1.41%
9Tweedy, Browne Co LLC 1.31%
10DEERFIELD MANAGEMENT COMPANY, L.P. 1.20%

Reported Ionis Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Ionis Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)24,556,637 14.86%Form 13F, quarter ended March 31, 2026
FMR LLC21,520,872 13.02%Proxy statement (DEF 14A), proxy filed April 23, 2026
Capital World Investors21,186,369 12.82%Schedule 13G, filed May 14, 2026
Vanguard Group16,440,459 9.95%Form 13F, quarter ended March 31, 2026
BlackRock10,442,476 6.32%Form 13F, quarter ended March 31, 2026
Two Sigma5,857,629 3.54%Form 13F, quarter ended March 31, 2026
State Street3,995,564 2.42%Form 13F, quarter ended March 31, 2026
T. Rowe Price3,025,251 1.83%Form 13F, quarter ended March 31, 2026
JPMorgan Chase2,363,567 1.43%Form 13F, quarter ended March 31, 2026
Goldman Sachs1,699,847 1.03%Form 13F, quarter ended March 31, 2026

Percentages above are of 165,262,556 shares outstanding, as reported by Ionis Pharmaceuticals, Inc. on its Form 10-Q dated April 23, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Ionis Pharmaceuticals, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 484 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 3,318 separate fund positions. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — Ionis Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Ionis Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ionis Pharmaceuticals, Inc.’s 10-Q dated April 23, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Ionis Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Ionis Pharmaceuticals (IONS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ionis-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.